A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.

Trial Profile

A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms TOMORROW
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 24 May 2017 Results published in the Boehringer Ingelheim media release.
    • 24 May 2017 According to a Boehringer Ingelheim media release, the company reported pooled analysis from this and other two trial (INPULSIS-1 and INPULSIS-2) at the 2017 American Thoracic Society (ATS) conference.
    • 25 Feb 2016 Results of pooled analysis published in the Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top